title: Management of HER2-positive breast cancer in Asia: consensus statement from the Asian Oncology Summit 2009.
abstract: Patients with breast cancer positive for human epidermal growth-factor receptor type 2 (HER2) are an important subgroup for consideration in the Asian context. Rationally designed, anti-HER2 targeted agents that can substantially improve treatment outcomes have become commercially available, but are still too costly for some groups in developed countries and for underdeveloped and developing nations. This review discusses the available evidence for optimum management of HER2-positive early and advanced breast cancer, and how this evidence can be applied to Asian countries with different levels of health-care resources and economic development--using framework provided by the Breast Health Global Initiative. We provide a brief overview of HER2 testing and discuss management of early and advanced HER2-positive breast cancer, and formulate a consensus statement for the management of breast cancer in the context of basic, limited, enhanced, and maximum health-care resource availability.
authors.affiliation: Department of Medical Oncology, National Cancer Centre, Singapore. dmowns@nccs.com.sg
authors.forename: Nan Soon
authors.initials: NS
authors.lastname: Wong
authors.forename: Benjamin O
authors.initials: BO
authors.lastname: Anderson
authors.forename: Kei Siong
authors.initials: KS
authors.lastname: Khoo
authors.forename: Peng Tiam
authors.initials: PT
authors.lastname: Ang
authors.forename: Cheng Har
authors.initials: CH
authors.lastname: Yip
authors.forename: Yen-Shen
authors.initials: YS
authors.lastname: Lu
authors.forename: Narind
authors.initials: N
authors.lastname: Voravud
authors.forename: Zhi-Ming
authors.initials: ZM
authors.lastname: Shao
authors.forename: Kathleen I
authors.initials: KI
authors.lastname: Pritchard
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D001208:Asia / Q000453:epidemiology; D014408:Biomarkers, Tumor / Q000032:analysis / Q000037:antagonists & inhibitors; D001943:Breast Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000191:economics / Q000201:enzymology* / Q000401:mortality / Q000556:secondary; D003226:Congresses as Topic; D003906:Developing Countries / Q000191:economics; D016527:Drug Costs; D055088:Early Detection of Cancer; D019317:Evidence-Based Medicine; D005260:Female; D019983:Guideline Adherence; D017048:Health Care Costs; D006297:Health Services Accessibility; D054625:Healthcare Disparities; D006801:Humans; D008495:Medical Oncology / Q000191:economics / Q000592:standards; D017410:Practice Guidelines as Topic; D011237:Predictive Value of Tests; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis / Q000037:antagonists & inhibitors; D016019:Survival Analysis; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D047428:Protein Kinase Inhibitors; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human